Expression of Programmed Death Ligand-1 (PD-L1) in Nasopharyngeal and Hyypopharyngeal Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05595265

Enrollment

Registered

2022-10-26

Start date

2022-11-30

Completion date

2023-11-30

Last updated

2022-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal and Hypopharyngeal Carcinoma

Brief summary

Head and neck tumors comprise heterogeneous neoplasms that arise from surface epithelium of different anatomic subsites in head and neck region such as oral cavity, oropharynx, larynx and hypopharynx. Nasopharyngeal and hypopharyngeal carcinomas represent 0.26 % of all cancers in Egypt. Tobacco exposure and alcohol dependence, and infection with oncogenic viruses such as human Papilloma virus (HPV) are among the risk factors for development of these tumors. Currently, the main treatment of nasopharyngeal and hypopharyngeal carcinomas is radio-chemotherapy based in histological type, grade and stages of the tumors Tumor infiltrating lymphocytes (TILs) are considered as cornerstone in cancer immunotherapy and as a biomarker with effectiveness predictive value. The intensity and quality of immune cells, especially lymphocytes, in tumor microenvironment are strongly related to the outcome of immune checkpoint blockade therapy .

Interventions

DIAGNOSTIC_TESTimmunohistochemical

Immunohistochemical Evaluation: Corresponding sections of 4µm thickness from each Formalin-fixed paraffin blocks will be immunohistochemically stained by anti- PD-L1 antibody according to the recommended protocol.

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* Patients with nasopharyngeal and hypopharyngeal carcinomas who underwent diagnostic biopsies.

Exclusion criteria

* Patients received chemotherapy or radiotherapy. * Patients with insufficient clinical data. * Specimens with extensive necrosis * Tiny specimens which are insufficient for accurate diagnosis.

Design outcomes

Primary

Measure	Time frame	Description
expression of programmed death ligand-1 (PD-L1) in nasopharyngeal and hypopharyngeal carcinoma	12 months	evaluate expression of PD-L1 in nasopharyngeal and hypopharyngeal carcinomas and to correlate its expression to different clinical and histopathological parameters to address its prognostic value.

Countries

Egypt

Contacts

Primary Contactnahawand m hafez, demonstrator

nahawendmohammed@med.sohag.edu.eg01008141816

Backup Contactahmed r hamed, professor

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026